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rash grade 1 to lower limbs after 10 days.
Immunogenicity was not assessed. None
of the patients developed influenza.
In conclusion, we did not observe
any relevant toxicity in patients with
NSCLC treated with concomitant influ-
enza vaccination and erlotinib. Although
influenza vaccines are not devoid of
risk, these data could assure clinicians
and patients that they are safe for this
subset of patients.
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Adjuvant Chemotherapy
in New Stage II pN0
Non-small Cell Lung
Cancer: A New Issue for
a Case-By-Case Decision
Making Process
To the Editor:
The seventh edition of the tumor,
node, metastasis (TNM) classification1
has raised some new issues in the adjuvant
chemotherapy decision-making process.
Previously, pN0 tumors 5 cm
were classified as stage Ib. In the new
classification, they become stage IIa
(5 but 7 cm) or stage IIb (7 cm)
because of a poorer prognosis than
smaller pN0 tumors.
According to this observation and
consistent with the Cancer-Care-Ontario
Program and the American Society of
Clinical Oncology guide-lines (based on
the sixth TNM edition),2 patients with
new stage II pN0 disease should be
informed on their prognosis, and adju-
vant chemotherapy could be proposed as
an individual option.
This issue should be carefully dis-
cussed for a case-by-case decision, ac-
cording to the available information. In
the absence of evidence-based data, we
underline the lack of definitive informa-
tion on the effect of adjuvant chemother-
apy in patients with pN0 nonsmall cell
lung cancer (NSCLC), irrespective of tu-
mor size.
As a matter of fact, this is true not
only for patients with sixth TNM stage Ib
tumors but also for patients with sixth
TNM pT3 pN0 disease. Although the lat-
ter population was gathered together with
patients with T1–T2 pN1 disease in stage
II and, so, considered for adjuvant chemo-
therapy according to ASCO guidelines, a
critical appraisal to this topic from an
extensive review of the literature showed
the absence of evidence-based data on the
efficacy of adjuvant chemotherapy for
sixth TNM pT3 pN0 tumors.3
Nevertheless, data from the CALGB
9633 phase III randomized trial should
also be shared with the patient. This trial
did not observe a significant survival ad-
vantage in patients with sixth TNM stage
Ib NSCLC, but it was underpowered to
answer this question in the population of
new stage II pN0 tumors, i.e., 5 cm.
Interestingly, in the subgroup of patients
with 4 cm disease (196 patients: 99
patients in the treatment arm and 97 pa-
tients in the control arm), there were a
significant advantage in overall survival
(hazard ratio: 0.69, 90% confidence in-
terval: 0.48–0.99) and disease-free
survival (hazard ratio: 0.69, 90% con-
fidence interval: 0.49–0.97).4
The lack of data in pT3 pN0 tumors
and the shift from stage I to stage II of
patients with 5 cm pN0 NSCLC raise
the need for information on the effects of
adjuvant chemotherapy in this subset of
patients. Major efforts to run a prospective
phase III trial to answer this question and
to select the subset of patients with higher
probability to benefit from this treatment
(if any) are warranted.
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A Systematic Review
but Systematically
Confounded?
To the Editor:
The study by Nair et al1 on the
prognostic value of positron emission to-
mography (PET) intensity in stage I non-
small cell lung cancer (NSCLC) is a su-
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perbly conducted systematic review, as
we have seen consistently from the senior
author. However, despite the scientific
rigor of the search and the analysis, I
worry that the conclusion is flawed due to
systematic confounding, emanating from
technical issues related to PET imaging
that are frequently overlooked.
The intensity of PET images corre-
lates with the amount of fluorodeoxyglu-
cose (FDG) in lesions over 2.5 cm. Below
this diameter, lesion size markedly affects
the intensity, as demonstrated by phantom
studies, in which a constant amount of
FDG activity seem less and less intense
when placed in a smaller diameter sphere
(Figure 1). This means that PET intensity
is progressively diminished for tumors
less than 2.5 cm, regardless of the meta-
bolic activity or accumulation of FDG in
the lesion. This has been confirmed both
in patient studies2 and in other investiga-
tions of the physics of PET imaging.3 This
also underscores a misconception about
the term “resolution” of a PET scanner,
which is a technical term and not the
lesion size that can be accurately imaged.
For example, at 1.5 times the resolution,
approximately 60% of the true activity is
measured, and measurement of 95% of the
true activity requires a lesion diameter
four times the resolution of the PET scan-
ner.3 The reasons for this are multiple and
complex, and partial volume averaging is
only part of the problem.
Because the relationship of detected
PET intensity and lesion size affects all stud-
ies, it results in systematic confounding (par-
ticularly for a study of stage I NSCLC!) that
no amount of meta-analysis can overcome
unless attention is paid to the size of each
tumor studied. It is unfortunate that the study
by Nair did not list at least the average
size or range of the tumors in each
study. Perhaps the authors have other
information that mitigates my concerns,
but there is no mention of possible con-
founding by size in the discussion.
There is likely also further sys-
tematic confounding due to inclusion of
both solid and ground glass opacities
lesions among the stage I tumors stud-
ied. NSCLC that appears as a ground
glass opacities usually has a more indo-
lent course,4 and these tumors have
much lower PET intensity as well.2
Of course, one can take a global
view that an association exists between
PET intensity and prognosis, even if the
data is confounded. However, application
of this observation becomes quite shaky if
we are unsure what really is the critical
factor. Note that multivariate analyses that
treat PET intensity and T stage as inde-
pendent variables are flawed because of
the strong correlation of size and PET
intensity. To make an analogy apropos to
using poorly understood associations, it
would be wrong to mandate a change of
music because of an association between
listening to hip-hop music and the rate of
car accidents, although it is probably true
that more teen drivers listen to hip-hop.
It is noteworthy that the only
study (prospective, multicenter) that ac-
counted for tumor size could not dem-
onstrate prognostic value to PET inten-
sity over that of stage alone.5 PET
intensity is complex, significantly de-
pendent on many factors (Table 1), and
requires further study and a sophisti-
cated approach if we are to appropriately
base clinical decisions on it.
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FIGURE 1. Effect of lesion size on the detected fluorodeoxyglucose (FDG) activity
in a phantom study of spheres of known size and activity placed in a cold back-
ground. Data taken from Clin Cancer Res 2000;6:3837–3844.6
TABLE 1. Factors Affecting Measurement of FDG Intensity
Factor Estimated Variance Description
Mean vs. max SUV 100% Definition of isocontour of volume of interest
Image resolution 10% Partial volume effect
Attenuation correction 10–50% CT vs. transmission attenuation
Nomalization 20% Actual weight vs. lean mass, BSA
Glucose level 10% 2 If high glucose
Delay after injection 20% 45 vs. 60 min post injection
Respiratory movement 20% Smearing, partial volume effect
Size 3 cm 50–80% 2 SUV if 2.5 cm (phantom study)
Data taken from J Thorac Oncol 2008:3:6–12.7
BSA, body surface area; CT, computed tomography; SUV, standardized uptake value; FDG, fluorodeoxyglucose.
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In Response:
We thank Dr. Detterbeck for
his interest and thoughtful comments
about our systematic review. We agree
with him that measuring fluorodeoxy-
glucose (FDG) uptake by using the stan-
dardized uptake value (SUV) is subject
to many different sources of impreci-
sion, as described in our discussion and
further delineated in his letter.
Several working groups have re-
cently developed guidelines for FDG
positron emission tomography (PET)
acquisition to help direct the research
community.1,2 These guidelines suggest
that the resolution of PET scanners
should be no less than half the tumor
size diameter. These same guidelines
suggest using a 12-mm region of interest
centered around the most intense FDG
uptake defined as “peak” SUV. Thus,
SUV measurements for tumors smaller
than 2.5 cm in size may yield important
clinical information.
We agree with Dr. Detterbeck that
tumor size is a potentially important
confounding variable, because it is
clearly associated with both the “expo-
sure” (FDG uptake) and, arguably, with
the outcome (survival). Accordingly,
multivariable analysis is both necessary
and sufficient to adjust for the confound-
ing influence of tumor size.3
Two studies in our systematic re-
view found that SUV was a significant
predictor of survival after adjusting for
tumor size.4,5 In addition, we recently
completed a study of prognosis in 75
patients with clinical stage Ia non-small
cell lung cancer (NSCLC) and found
that SUV was a significant predictor of
survival both before and after adjust-
ment for tumor size (hazard ratio: 1.21,
95% confidence interval 1.01–1.45 per 1
unit increment in SUVmax). There was a
significant interaction between SUVmax
and tumor size, such that the magnitude of
the association between FDG uptake and
survival was even stronger for patients
with tumors larger than 18 mm (mean
tumor diameter in our study).6 Of note,
only three of the nine studies in our review
provided data on tumor size for patients
with stage I NSCLC; in these studies, the
mean diameters were 14, 24, and 31 mm,
respectively.4,7,8 We did not examine the
effect of histology or attenuation charac-
teristics because this information was not
provided in the primary studies.
We continue to believe, along
with others in the field, that a large,
prospective, multicenter trial using stan-
dardized protocols is necessary to fully
examine the potential use of PET FDG
uptake as a biomarker for prognosis in
NSCLC. We hope that our review stim-
ulates additional interest in performing
such a study.
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